程序性死亡受体1 (programmed cell death protein 1, PD-1, 又称CD297)是由 Pdcd1编码的Ⅰ型跨膜蛋白, 是CD28免疫球蛋白超家族的一员。PD-1表达于多种肿瘤组织中的肿瘤浸润型淋巴细胞, 包括头颈部癌、黑色素瘤和…
Anti-PD-L1 Therapy Yielded Durable Responses in Early NSCLC Trials
Online literature searches were performed via PubMed, PubMed Central, and Google using the keywords “immune checkpoint inhibition”; “host-directed therapy”; “T cell exhaustion”; “cancer immunotherapy”; “anti-PD-1 therapy”; “anti-PD-L1 therapy”; “chronic infections”; “antigen-specif...
"In all, these 3 exciting trials combining PD-1 or PD-L1 inhibition with targeted therapy, chemotherapy, or immune cell therapy bode well for evolving advances with this tolerable class of agents." Robert L. Ferris, MD, PhD Even during times of coronavirus disease 2019, exciting cancer rese...
These antibodies impede immune checkpoint receptors, including PD-1/PD-L1, and their combination therapy shows promise in the treatment of advanced CRC. This review presents a concise overview of the use of the PD-1/PD-L1 blockade as a therapeutic strategy for CRC using monoclonal antibodies ...
在《anti-PD-(L)1联合用药策略》上两集里,介绍了肿瘤免疫周期和三类肿瘤,并聚焦肿瘤免疫周期的前三个阶段—察觉 渗入和破境。在本集里,我们将讨论肿瘤免疫周期的最后阶段:歼灭。
近日,上海交通大学药学院路慧丽团队在Molecular Therapy期刊上发表题为:A novel anti-PD-L1/IL-15 immunocytokine overcomes resistance to PD-L1 blockade and elicits potent antitumor immunity的研究成果。 该团队将IL-15Rα-sushi doma...
PROGRAMMED death-ligand 1The ability of cancer cells to ensure T-cell exclusion from the tumor microenvironment is a significant mechanism of resistance to anti-PD-1/PD-L1 therapy. Evidence indicates crucial roles of Batf3-dependent conventional type-1 dendritic cells (cDC1s) for inducing ...
Immunotherapy, especially anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) treatment has significantly improved the survival of non-small cell lung cancer (NSCLC) patients. However, the overall response rate remains unsati
anti-PD1 therapyBackground: Anti-PD-1 therapy has been approved for cancer treatment. However, the response rate is unsatisfactory. The expression of PD-L1 in tumor tissues affdoi:10.2139/ssrn.3514597Zhang, ChaoxuFan, YiboChe, Xiaofang